Publications
Featured Publications
Bourgeois W, Cutler JA, Aubrey BJ, Wenge D, Perner F, Martucci C, Henrich JA, Klega K, Nowak RP, Donovan KA, Boileau M, Wen Y, Hatton C, Apazidis AA, Olsen SN, Kirmani N, Pikman Y, Pollard JA, Perry JA, Sperling AS, Ebert BL, McGeehan GM, Crompton BD, Fischer ES, Armstrong SA.
Blood. 2023 Dec 14:blood.2023021105. doi: 10.1182/blood.2023021105. Online ahead of print.PMID: 38096371
MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F, Wenge DV, Kim J, Apazidis A, Rahnamoun H, Anand D, Marinaccio C, Hatton C, Wen Y, Stone RM, Ener E, Cutler JA, Doench JG, Nowak RP, Fischer ES, Armstrong SA
Nature. 2023 Mar;615(7954):913-919. doi: 10.1038/s41586-023-05755-9. Epub 2023 Mar 15.PMID: 36922589.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM.
Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15. PMID: 36922593; PMCID: PMC10060155.
Significance
We uncovered an important functional role of mutant NPM1 as a crucial direct driver of oncogenic gene expression in AML. NPM1c can bind to chromatin and cooperate with the MLL complex, providing the first functional insight into the mechanism of Menin–MLL inhibition in NPM1c leukemias.
Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia
Uckelmann HJ, Haarer EL, Takeda R, Wong EM, Hatton C, Marinaccio C, Perner F, Rajput M, Antonissen NJC, Wen Y, Yang L, Brunetti L, Chen CW, Armstrong SA
Cancer Discov. 2022 Dec 1:CD-22-0366. doi: 10.1158/2159-8290.CD-22-0366.
Graphic from Jones, L.M., Starczynowski, D.T. Nat Cancer 3, 528–529 (2022).
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia
Aubrey BJ*, Cutler JA*, Bourgeois W*, Donovan KA, Gu S, Hatton C, Perlee S, Perner F, Rahnamoun H, Theall ACP, Henrich JA, Zhu Q, Nowak RP, Kim YJ, Parvin S, Cremer A, Olsen SN, Eleuteri NA, Pikman Y, McGeehan GM, Stegmaier K, Letai A, Fischer ES, Liu XS, Armstrong SA
Nat Cancer. 2022 May;3(5):595-613. doi: 10.1038/s43018-022-00366-1. Epub 2022 May 9.PMID: 35534777
MOZ and Menin-MLL Complexes are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor
Hemming ML, Benson MR, Loycano MA, Anderson JA, Andersen JL, Taddei ML, Krivtsov AV, Aubrey BJ, Cutler JA, Hatton C, Sicinska E, Armstrong SA
Cancer Discov. 2022 Jul 6;12(7):1804-1823. doi: 10.1158/2159-8290.CD-21-0646. PMID: 35499757.
MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape
Olsen SN, Godfrey L, Healy JP, Choi YA, Kai Y, Hatton C, Perner F, Haarer EL, Nabet B, Yuan GC, Armstrong SA
Mol Cell. 2022 Mar 17;82(6):1140-1155.e11. doi: 10.1016/j.molcel.2022.02.013. Epub 2022 Mar 3. PMID: 35245435; PMCID: PMC9044330.
The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, Barwe SP, Gopalakrishnapillai A, Xu H, Uckelmann HJ, Takao S, Kazansky Y, Pikman Y, McGeehan GM, Kolb EA, Kentsis A, Armstrong SA
Blood. 2021 Sep 28:blood.2021012806. doi: 10.1182/blood.2021012806.
Histone PTM Crosstalk Stimulates Dot1 Methyltransferase Activity
Cutler JA, Perner F, Armstrong SA
Trends Biochem Sci. 2021 Jul;46(7):522-524. doi: 10.1016/j.tibs.2021.04.001.
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
Uckelmann HJ, Kim SM, Wong EM, Hatton C, Giovinazzo H, Gadrey JY, Krivtsov AV, Rücker FG, Döhner K, McGeehan GM, Levine RL, Bullinger L, Vassiliou GS, Armstrong SA
Science. 2020 Jan 31;367(6477): 586-590. doi: 10.1126/science.aax5863
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
Krivtsov AV, Evans K, Gadrey JY, Eschle BK, Hatton C, Uckelmann HJ, Ross KN, Perner F, Olsen SN, Pritchard T, McDermott L, Jones CD, Jing D, Braytee A, Chacon D, Earley E, McKeever BM, Claremon D, Gifford AJ, Lee HJ, Teicher BA, Pimanda JE, Beck D, Perry JA, Smith MA, McGeehan GM, Lock RB, Armstrong SA
Cancer Cell. 2019 Dec 9;36(6):660-673. doi: 10.1016/j.ccell.2019.11.001.
*Featured in Menin Inhibitors: A New Hope in MLL Rearranged Leukemia?
A complete list of publications can be viewed here.
*These authors contributed equally, Bold denotes Armstrong lab members.